Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes

What Was Tested

Researchers studied Lixisenatide in the context of low blood pressure and orthostatic hypotension in this randomized controlled trial publication.

Who Took Part

The abstract describes 15 participants taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Fifteen healthy participants (nine men, six women; mean ± SEM age 67.2 ± 2.3 years) and 15 participants with T2DM (nine men, six women; mean ± SEM age 61.9 ± 2.3 years) underwent measurement of gastric emptying, BP, SMA flow and plasma glucose 180 minutes after a radiolabelled 75-g glucose drink on two separate days.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Lixisenatide and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Lixisenatide.

The comparison arm used a placebo, so changes seen with Lixisenatide could be set against what happens without it.

Each person switched between Lixisenatide and the comparison at some point, usually with a gap in between.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Gastric Emptying, Healthy Volunteers, Heart Rate and Peptides.

The authors tagged it with the keywords lixisenatide, postprandial hypotension and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Lixisenatide in 15 participants in people with low blood pressure and orthostatic hypotension.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Lixisenatide compound page, Low blood pressure and orthostatic hypotension research.